Iris Grossman

5 Basel St
Petah Tiqwa, M 49131, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Author Correction: Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Author Correction: Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Journal: Scientific reports

Published: April 23, 2024

Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Journal: Scientific reports

Published: May 18, 2023

Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.

Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.

Journal: Frontiers in pharmacology

Published: November 20, 2020

Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006.

Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19-30.https://doi.org/10.1016/j.ensci.2018.05.006.

Journal: eNeurologicalSci

Published: November 09, 2018

Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.

Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.

Journal: BMC medical informatics and decision making

Published: September 02, 2018

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.

Journal: eNeurologicalSci

Published: April 16, 2018

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Journal: Molecular neurodegeneration

Published: April 09, 2018

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Journal: Annals of the New York Academy of Sciences

Published: August 03, 2017

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Journal: JCI insight

Published: July 05, 2017

Biobanking in Israel 2016-17; expressed perceptions versus real life enrollment.

Biobanking in Israel 2016-17; expressed perceptions versus real life enrollment.

Journal: BMC medical ethics

Published: June 13, 2017

Drug repurposing from the perspective of pharmaceutical companies.

Drug repurposing from the perspective of pharmaceutical companies.

Journal: British journal of pharmacology

Published: February 07, 2017

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Journal: Genome medicine

Published: December 08, 2016

Showing 1-12 of 26

Last Updated: 09/26/2026